On November 6, 2025 Servier reported that it will present new and updated data at the 67th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), December 6-9, 2025, in Orlando, Florida. Presentations will highlight clinical and real-world data from Servier’s hematology portfolio and underscore Servier’s leadership in isocitrate dehydrogenase (IDH) mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Notably, Servier will present an updated response and safety analysis from a Phase 1 study of TIBSOVO (ivosidenib) combined with intensive chemotherapy in newly diagnosed IDH1-mutated AML in an oral presentation on Monday, December 8 at 4:45 p.m. The data demonstrate the addition of TIBSOVO to intensive induction and consolidation chemotherapy followed by single-agent TIBSOVO maintenance produces long-term responses with an acceptable safety profile. The benefit of this frontline regimen is being assessed in a Phase 3 randomized, blinded trial.
"Servier’s presentations at this year’s ASH (Free ASH Whitepaper) Annual Meeting reflect our ongoing commitment to maximizing the potential of the medicines in our portfolio, leaving no stone unturned as we endeavor to deliver innovative treatment options to as many eligible patients as possible, said Becky Martin, PhD, Chief of Medical, Servier Pharmaceuticals. "We’re expanding our existing understanding of the clinical benefits of TIBSOVO to uncover its full potential in AML and MDS, while simultaneously advancing the research and development of investigational treatment options in our growing hematology pipeline."
(Press release, Servier, NOV 6, 2025, https://www.prnewswire.com/news-releases/serviers-new-and-updated-data-at-2025-ash-annual-meeting-highlight-commitment-to-hematology-research-302606336.html [SID1234659614])